CMO Diego Cadavid, M.D. to present data for Phase 1 of VRG50635 at ENCALS 2023

We are proud that Verge's CMO Diego Cadavid, M.D. will be joined by colleagues to present data from our Phase 1 study of VRG50635, a PIKfyve inhibitor for the potential treatment of ALS, during this week’s European Network to Cure ALS (ENCALS) 2023 meeting in Barcelona, Spain on July 13 - 14